The proinflammatory cytokine, tumour necrosis factor (TNF ) has been shown to play a pivotal part in mediating acute and chronic inflammation. The activities of TNF are modulated by the proteolytic shedding of the soluble extracellular domains of the two TNF receptors, p55 sTNF-RI and p75 sTNF-RII. Amgen Inc has cloned and expressed a recombinant form of a natural inhibitor of TNF , referred to as recombinant human soluble TNF receptor type I (r-Hu-sTNF-RI, sTNF-RI). sTNF-RI is an E coli recombinant, monomeric form of the soluble TNF-type I receptor. A high molecular weight polyethylene glycol (PEG) molecule is attached at the N-terminus position to form the molecule intended for clinical evaluations (PEG sTNF-RI). Preclinical studies to date demonstrate that PEG sTNF-RI is eYcacious in rodent models of chronic inflammatory disease including rheumatoid arthritis and Crohn's disease at doses as low as 0.3 mg/kg given every other day. This dose results in plasma concentrations of 0.3 to 0.5 µg/ml. Higher doses with correspondingly higher plasma concentrations yield higher eYcacy. It has also demonstrated eYcacy in E coli lipopolysaccharide, and Staphylococcus enterotoxin B mediated models of acute inflammation in rodents and primates. Pharmacokinetic studies in mice, rats, cynomolgus monkeys, baboons, and chimpanzees have been conducted with PEG sTNF-RI. Absorption from a subcutaneous dose was slow, with the time to reach maximal plasma concentrations of 24-48 hours in rats, and in monkeys, and 3-29 hours in chimpanzees. The initial volume of distribution of PEG sTNF-RI was essentially equivalent to that of plasma (40 ml/kg). This suggests the protein does not appear to extensively distribute from the systemic circulation with a volume of distribution at steady state (Vss) less than 200 ml/kg in all species studied. These results are consistent with previous experience with PEGylated proteins in which PEGylation decreases both the rate of absorption and the plasma clearance of human recombinant proteins in animals and humans. The use of a PEG molecule will probably provide a more advantageous dosing schedule (that is, less frequent dosing) for the patient compared with a non-PEG sTNF-RI.
During the past decade, the understanding of immunopathological reactions has greatly evolved as a result of the characterisation of cytokines and interleukins that regulate the interactions not only between cells of the immune system, but also between the immune system and other tissues and cells, such as endothelial cells, fibroblasts, and adipocytes. One cytokine that is increasingly recognised as a central mediator in a wide spectrum of physiological and immune functions is macrophage derived tumour necrosis factor (TNF ) or cachectin. Although much remains to be elucidated about this molecule, TNF has been found to mediate eVects as diverse as tumoricidal activity, 1 wasting associated with chronic disease, 2 and the recruitment of both immune and non-immune cells to participate more eVectively in the host response to an invasive agent. In addition, an increasingly large body of evidence indicates that TNF serves as an important mediator in the evolution of acute 3 and chronic inflammatory diseases. 4 5 As stated in the introduction, TNF is also referred to as cachectin, 6 and this cytokine has a wide range of biological eVects. 3 7 These eVects include anti-tumour activity, 3 6 mediation of endotoxic shock and cachexia in infectious disease, 8 9 augmentation of superoxide anion (O 2 -) and hydrogen peroxide (H 2 O 2 ) release by neutrophils and macrophages, 10 inhibition of viral replication, and potentiation of non-viral pathogen destruction by macrophages in vitro and in vivo. 2 These studies and numerous others point out that TNF is a major physiological cytokine important in mediating normal homeostatic mammalian processes. 5 11 TNF exists as a trimer of three identical subunits. 10 12 13 Signal transduction occurs when TNF binds to, and dimerises two receptors of either the p55 (TNF-RI) or p75 (TNF-RII) subtype on the cell surface. 14 Numerous biological eVects of TNF are mediated following intracellular signalling with the high aYnity p55 TNF receptor (TNF-RI). 15 Naturally occurring TNF inhibitors, consisting of the full length 4 domain or truncated forms of the extracellular region of TNF-RI, 16 are referred to as tumour necrosis factor binding proteins (TNFbp) or soluble TNF receptor (sTNF-RI). These molecules have been found in active human rheumatoid arthritic disease tissue, serum, synovial fluid, and synovial explant cultures. The presence of sTNF-RI has been shown to correlate to rheumatoid arthritis (RA) disease activity. 17 Recombinant human soluble tumour necrosis factor receptor type I (sTNF-RI) has been cloned and isolated by recombinant DNA techniques using E coli 18 19 as a host. Numerous preclinical animal model studies designed to test the eYcacy of PEG sTNF-RI have demonstrated reproducible, potent antiinflammatory, anti-cytokine, and bone and cartilage sparing eVects. [20] [21] [22] [23] A wide array of biological agents have been designed to inhibit TNF , including specific anti-human TNF monoclonal antibody, [24] [25] [26] soluble TNF receptor fusion constructs, 19 27 28 and soluble TNF receptor binding proteins. [27] [28] [29] [30] [31] Several synthetic inhibitors of TNF biosynthesis have also been described. 7 32 33 The use of soluble TNF receptors, or TNF binding proteins, has also recently been tested in animal models and in the clinic. 30 34-37 It has been postulated that TNF-RI and TNF-RII normally function as TNF buVers and slow release reservoirs, depending on the relative concentrations of TNF and the respective biochemical properties of the two receptors. 38 39 These very diVerent kinetics of binding of TNF to the two TNF receptors has raised speculation that in vivo, the two receptors may have fundamentally diVerent functions. The TNF type II receptor may serve as a "ligand passer"-that is, a means to deliver or pass TNF to the type I receptor for signalling when concentrations of TNF are low. 40 Support for this hypothesis that the primary function of the TNF type II receptor is a ligand passer is the observation that under in vivo conditions, the primary inflammatory responses to soluble 17 k D TNF are mediated by TNF-RI, and not TNF-RII signalling. 41 Because of the higher aYnity with the TNF type I receptor greater potential clinical benefit may be realised. 15 36 42 The balance or imbalance between cytokines and their natural inhibitors seems to play a very important part in RA. 43 As RA is a long term chronic disease, any therapeutic agent designed to alleviate the inflammation and downstream destruction in the joint must be eYcacious for a number of years after multiple administrations to the patient.
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Evidence that TNF is a mediator of clinical diseases TNF , a polypeptide cytokine, was discovered on the basis of its induction of haemorrhagic necrosis in certain murine tumours in vivo, and, independently, as a bloodborne mediator of cachexia during parasitic disease. 7 It is produced by activated macrophages, T cells, and other cells, and has many activities in the immune system and in other systems. TNF is a potent molecule that stimulates the production of many cytokines, including IL1, IL6, GM-CSF, IL8, and secretion of degradatory molecules including several metalloproteinases. 33 44 TNF mediates the cytokine cascade that causes inflammation and joint destruction in RA. 45 46 TNF concentrations are increased in rheumatoid synovial fluids, particularly in patients with severe disease or with high concentrations of white blood cells in the synovial fluid. 17 47 TNF is abundant in macrophages in the rheumatoid synovial membrane and TNF containing cells are localised to the pannus (articular cartilage in the joints of patients with RA), suggesting production near the site of tissue destruction. 48 Furthermore, TNF receptors are localised to macrophages and fibroblasts in the rheumatoid synovial lining layer, as well as to lymphocytes and endothelial cells in the subsynovial membrane, which suggests that a variety of cells in the rheumatoid synovial membrane are potential targets for TNF. 49 50 As stated previously, two distinct TNF receptors (TNFRs) have been identified: the 75 k D or p75 receptor type II and the 55 k D or p55 receptor type I (formerly referred to as p80 and p60, respectively 13 39 ). Both the TNF type-I and type-II receptors exist as cell-surface and soluble forms and both forms bind TNF, although with diVerent aYnities. 15 40 41 51 TNF cell surface receptors are present on virtually all cell types, including macrophages, lymphocytes, and neutrophils. TNF must bind to two or three cell surface receptor molecules for signalling to occur, resulting in a biological eVect. Binding to a single cell surface receptor does not result in signalling.
Monomeric fragments that comprise the extracellular portion of the cell surface receptors are naturally occurring forms resulting from proteolytic cleavage, and then are referred to as soluble TNFRs (sTNFRs). 7 sTNFRs are ubiquitous, and increased concentrations of sTNFRs have been found in the circulation of patients with RA. 50 52 53 sTNFR concentrations, measured by enzyme linked immunosorbent assay, are higher in synovial fluid samples compared with serum sample concentrations in patients with RA.
47
Clinical evidence that TNF is a mediator of RA RA is a heterogeneous, systemic disease of unknown aetiology, and persons with RA typically develop inflammation of joint synovium. 54 55 Clinical symptoms become apparent with progression of synovitis resulting from production and release of cytokines from activated macrophages, along with the activation of T lymphocytes, angiogenesis, and attraction of neutrophils to the joint cavities. Cellular expression of major histocompatibility complex (MHC) class II molecules within the joint microenvironment is a predominant feature of RA, and this expression induces production of a complex network of cytokines. Cytokines induce synovial cell proliferation, resulting in invasion and destruction of articular cartilage. Synovial fibroblasts are thought to become activated by proinflammatory mediators such as TNF to secrete a large variety of cytokines and growth factors. 46 Activities ascribed to TNF in RA include recruitment and activation of polymorphonuclear leucocytes (PMNs), cellular proliferation, increased prostaglandin and matrix degrading protease activity, fever, and bone and cartilage resorption. 4 56 Rheumatoid synovial fluid seems to include predominantly macrophage derived products such as IL1 , IL1 , IL6, TNF , and IL8, although there has been disagreement over the exact cytokine composition. 57 The relative cytokine composition of synovial fluid may be influenced in vivo by variables such as disease severity and stage of progression. IL8 (neutrophil chemotactic factor) may be responsible for the accumulation of neutrophils in the joint cavity, and its production may be stimulated by IL1 and TNF . TNF and TNF induced IL1 stimulate the synthesis of collagenase and stromelysin by synoviocytes, thereby contributing to the loss of normal joint integrity and function.
The concept that TNF is a major mediator of the inflammatory response in the aVected joints of rheumatoid arthritic patients is now well recognised. Studies using cA2, a chimeric (mouse × human) Mab, have demonstrated significant eVects in short-term and long term duration clinical trials (Inflixamab, Centocor, Inc). 24 58 An unexpected side eVect in these trials was the development of IgM class anti-ds-DNA antibodies, which has raised the question of patients developing lupus-like syndromes with long term Mab treatment. 59 Other humanised anti-TNF Mab have also been tested in the clinic with variable results. 60 A p55 TNF-RI IgG 1 immunoadhesion molecule demonstrated short-term eYcacy in European and North American phase 2 clinical trials; however, the immunogenicity of this molecule aVected drug clearance after multiple intravenous injections. 61 Results from phase 2 and 3 extension studies using Enbrel, a p75 sTNF-RII IgG 1 immunoadhesion molecule have been published. 62 63 These results suggest that the p75 sTNF-RII IgG 1 immunoadhesion molecule can be safely administered to RA patients for at least a period of six months. 37 64 In a dose escalation safety study in patients with refractory RA, the administration of the p75 sTNF-RII IgG 1 immunoadhesion molecule produced no clinically significant side eVects and decreased C reactive protein levels and numbers of swollen joints. 37 64 These initial encouraging results were reproduced in a multicentre, placebo controlled trial. 63 Seventy five per cent of patients receiving the highest dose of the p75 sTNF-RII IgG 1 immunoadhesion molecule achieved at least a 20% clinical response according to American College of Rheumatology (ACR) criteria. No antibodies against the drug were reported, although injection site reactions and upper respiratory infections were observed in several patients. This drug was previously tested in septic shock. 35 Recently the pivotal phase 3 studies were published with this molecule. 63 As mentioned above, the immunogenicity of the TNFbp PEGylated Dimer molecule negatively impacted the clearance rate of the molecule, and reduced the serum half life in the phase 1/2 clinical trial and was therefore, determined as not suitable for a chronic indication. 65 However, proof of concept was demonstrated by a decrease in swollen and tender joints over a 21 day period. 65 The
TNFbp PEGylated Dimer was replaced with a second generation, monomeric sTNF-RI formulation, PEG sTNF-RI, which oVers the following advantages: (1) minimal immunogenicity, (2) high degree of eYcacy in animal models of RA, and (3) minimal toxicological impact in animal models.
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Rationale for the design of the PEG r-Hu-sTNF-RI molecule Amgen previously conducted two clinical studies using another high aYnity soluble TNFtype I receptor (r-HuTNFbp PEGylated Dimer, TNFbp Dimer). 65 In the initial study, human anti-TNFbp antibodies were generated after a single intravenous dose in normal volunteers. In RA patients the TNFbp Dimer demonstrated preliminary eYcacy after single and multiple doses, however, the appearance of antibodies correlated with increased clearance and shorter half life after multiple doses. These antibodies were neither neutralising nor cytotoxic. Further development of the TNFbp PEGylated Dimer for a chronic indication such as RA became a concern because of the immunogenicity of this molecule. 65 Amgen initiated several studies to identify and develop backup and second generation soluble TNF-type I receptors. These studies included: Dimer after single and repeated administration in the previous clinical trials, and 9 Testing the various analogues in pharmacokinetic, toxicology, and pharmacology studies. At the conclusion of these studies, Amgen selected PEG sTNF-RI as the optimal molecule for clinical evaluation. This molecule was chosen because it demonstrated a favourable pharmacokinetic profile based upon parameters such as bioavailability, plasma clearance, and terminal half life. 66 It was also the least immunogenic and antigenic molecule, and demonstrated eYcacy in animal models that have been previously used to predict activity of agents currently used in treatment of RA. Thus PEG sTNF-RI was designated as the clinical candidate (fig 1) .
In vitro activity of the PEG r-Hu-sTNF-RI PEG STNF-RI L929 CYTOTOXICITY ASSAY RESULTS
The L929 Bioassay 67 was used to test the activity of PEG sTNF-RI (table 1). The reference standards used for PEG sTNF-RI were the unPEGylated (r-Hu-TNFbp) and r-Hu-TNF-bp PEGylated Dimer. The data show that the PEG sTNF-RI is active and, when compared with the standards, has comparable specific activities and EC 50 (eVective concentration) values within the range of the standard.
PEG STNF-RI RHEUMATOID ARTHRITIC EXPLANT SYNOVIAL CELL BIOASSAY RESULTS
The eYcacy of PEG sTNF-RI at the cellular and molecular level was assessed in an ex vivo synovial cell bioassay using RA patient target tissue and tissue similar to synovial cells in the aVected joint. 68 In this assay system, TNF (10 ng/ml) is added to the cells in vitro and inflammatory products such as prostaglandin E 2 (PGE 2 ) and matrix metalloproteinase 1 (MMP-1) are measured by ELISA at +24 hours of cell culture. In this assay system, PEG sTNF-RI displayed dose related inhibition of TNF induced PGE 2 production with an IC 50 (inhibitory concentration) of 25 nM (fig 2) . A purified control preparation of the human TNF Type I receptor resulted in an IC 50 of > 85 (fig 2) . These data demonstrate similar activities with both receptor preparations.
BINDING AFFINITY PROPERTIES OF PEG STNF-RI
It was recently shown that the p55 TNF receptor type I (TNF-RI) is the high aYnity receptor for soluble TNF. 15 To determine the ability of PEG sTNF-RI to bind to recombinant human TNF , a BIAcore ligand binding assay was used. 51 As shown in table 2, PEG sTNF-RI binds TNF with high aYnity (K D = 557 pM). The K D values of E coli derived and CHO cell derived sTNF-RI are 794 pM and 338 pM respectively (table 2) . Finally, as previously shown, 51 the dimeric form of sTNF-RI (rHuTNFbp PEGylated Dimer) has a higher binding aYnity (K D = 240 pM) than either the recombinant E coli derived or CHO cell derived forms of sTNF-RI (table 2) .
PEG R-HU-STNF-RI IN THE ADJUVANT ARTHRITIS

MODEL
Immunisation of rats with Freund's complete adjuvant (day 0) causes an immunologically mediated polyarthritis with histological features resembling those of human RA. 21 Onset of clinical arthritis usually occurs on day 9. The PEG sTNF-RI was given subcutaneously every other day (Q2D) on days 9, 11, and 13. Diameter of the ankle joints was measured with a caliper on day 8 or 9 and from days 11 to 15; body weights were also determined on these days. Blood was collected on day 11 before dosing for determination of serum PEG sTNF-RI concentrations. All animals were killed on day 15, blood was collected for determination of serum PEG sTNF-RI concentrations, and hind paws and spleens were removed, weighed, and processed for histopathological evaluation.
Treatment with PEG sTNF-RI significantly inhibited the body weight eVects of adjuvant disease (fig 3) and the diameter of ankle joints over the course of arthritis (expressed as area under the curve (AUC), % inhibition) (fig 4) . Compared with vehicle treated animals, treatment with PEG sTNF-RI at 9 mg/kg or 3 mg/kg reduced the final paw weights by 57% and 45%, respectively, and reduced the relative spleen weights by 58% and 59%, respectively. On day 11, concentrations of PEG sTNF-RI in serum in the 9 mg/kg and 3 mg/kg groups were (mean (SEM)) 10.4 (0.5) µg/ml and 3.2 (0.2) µg/ml, respectively. On day 15, concentrations of PEG sTNF-RI in serum were 12.2 (1.1) µg/ml and 4.0 (0.2) µg/ml, respectively. On histopathological analysis, treatment with PEG sTNF-RI significantly reduced the amount of inflammation and bone resorption in the ankle joints of treated rats compared with vehicle treated rats ( fig 5) . An additional dose response study of PEG sTNF-RI was done in this model to evaluate the potential eYcacy of lower doses. Arthritic rats given subcutaneous doses of 3, 1, or 0.3 mg/kg on days 9, 11, 13 (as in previous study) had significant inhibition of final paw weights and AUC values for paw swelling. 23 Histological parameters of bone resorption and inflammation were also beneficially aVected by treatment with PEG sTNF-RI. 23 Another set of animals were given single subcutaneous doses (3, 1, or 0.3 mg/kg) of PEG sTNF-RI and blood samples were obtained at intervals for determination of plasma profile associated with eYcacy. These data demonstrate that plasma concentrations less than or equal to 0.5 µg/ml over the 48 hours of the dosing interval were associated with eYcacy. Higher plasma concentrations increased the eYcacy.
PEG R-HU-STNF-RI IN THE RAT STREPTOCOCCAL INDUCED ARTHRITIS MODEL
The streptococcal cell wall (SCW) model of arthritis in female Lewis (LEW/N) rats is used to study reactivation of arthritis similar to arthritic flares in the human disease. 69 70 Arthritis was induced with an intra-articular injection of SCW (1.5 mg/10 ml) into the ankle joints. Three weeks post intra-articular injection the arthritis was reactivated by an intravenous injection of a subarthritogenic dose of SCW (200 µg/200 µl) with drug treatment of the rats beginning one day before the reactivation. Paw swelling was assessed on days +21, +22, +23, and +24. A series of studies was conducted to assess the eVects of PEG sTNF-RI in this model. PEG sTNF-RI (3 mg/kg body weight, subcutaneously) showed a significant (p < 0.05) reduction in ankle width and histological parameters when compared with the disease control group in this model ( fig 6 and fig 7) . In the second phase of the study, PEG sTNF-RI was administered to SCW challenged rats in a dose related fashion (0.1 m/kg-3 mg/kg body weight subcutaneously). Significantly (p < 0.05) reduced swelling in comparison with the disease-control rats occurred to +3 days after injection at the highest doses (fig 8) . Mean histology scores were significantly (p < 0.05) diVerent for PEG sTNF-RI treated rats at the high dose groups when compared with disease controls (fig 9) . These data suggest that PEG sTNF-RI is highly eYcacious in a rodent RA model that mimics acute flares in human RA. 
Interpretation of results and conclusions from rodent models of RA
Results of preclinical studies in rat arthritis models demonstrate that eYcacy occurs at doses of PEG sTNF-RI as low as 0.3 mg/kg given every other day. This dose results in plasma concentrations of 0.3-0.5 µg/ml over the 48 hour dosing interval. Higher doses with higher plasma concentrations demonstrate the dose responsive eYcacy on clinical parameters such as joint swelling as well as the important histological parameter of bone destruction. Maximal eVects occur when plasma concentrations are maintained in the range of 3-5 µg/ml (based on continuous infusion studies with monomeric TNF-RI). Additive combination benefit occurs when PEG sTNF-RI is given at these same doses with IL1ra, methotrexate, indomethacin, or dexamethasone. Taken together, these results in preclinical models of arthritis suggest that PEG sTNF-RI should have anti-arthritic activity in patients when plasma concentrations are in the 0.3 to 5 µg/ml range. 21 23 71 Combination studies with currently used anti-rheumatic agents suggest a strong potential for additive benefit.
Pharmacokinetics and metabolism in animals
Studies have been performed in mice, rats, cynomolgus monkeys, baboons, and chimpanzees to define the plasma pharmacokinetics of PEG sTNF-RI. 72 Multiple dose studies were conducted to determine dose and time linearity and any changes over time in PEG sTNF-RI plasma concentrations that could be related to the production of antibodies. In all of the species studied (except mice), the elimination of PEG sTNF-RI from plasma was biphasic, thus both alpha and beta half lives are presented in table 3. It is important to note that a significant portion of the dose is eliminated by the alpha phase in the higher species, particularly in chimpanzees, and thus predicted to occur in humans. Absorption from a subcutaneous dose was slow, with the time to reach maximal plasma concentrations of 24-48 hours in rats, 36 hours in monkeys, and 12-48 hours in chimpanzees. Systemic bioavailability after a subcutaneous dose of PEG sTNF-RI in rats and monkeys was determined to be 70% in rats and approximately 100% in monkeys. The initial volume of distribution (Vd) in rats, monkeys, baboons and chimpanzees (Vd/F, where F is the systemic bioavailability) was essentially equivalent to that of plasma (40 ml/kg). At steady state, the volume of distribution was less than 200 ml/kg in all species studied (table 3   72 ). This suggests that PEG sTNF-RI does not distribute extensively outside of the plasma compartment. Average plasma clearance in all species was much less than the renal filtration rate, indicating other routes of elimination may be important. The volume of distribution and plasma clearance across species on a per body weight basis was relatively constant. This is consistent with the correlation observed between elimination half lives and body weight. Thus, a 70 kg human is predicted to distribute and eliminate PEG sTNF-RI very much like a 50 kg chimpanzee. Given these data, the dose and dose schedules for the first clinical trial in humans have been projected based on the pharmacokinetic model of PEG sTNF-RI in chimpanzees.
Upon multiple dosing in primates, PEG sTNF-RI was observed to follow both time and dose linear plasma pharmacokinetics with respect to maximal plasma concentrations, area under the plasma concentration versus time curves, and plasma clearance. PEG sTNF-RI did not accumulate in the plasma of baboons administered a 0.2 mg/kg intravenous dose every three weeks (total of three doses), or in the plasma of cynomolgus monkeys given twice weekly subcutaneous injections ranging from 0.25 mg/kg to 25 mg/kg PEG sTNF-RI for four weeks (total of eight doses). In chimpanzees given weekly or twice weekly subcutaneous 0.5 mg/kg doses (total of four doses), mild to moderate accumulation was observed. Antibodies to PEG sTNF-RI were not detected in the serum of any of the primate species after either single or multiple doses (fig 10   72 ).
Projections for human dosing based on preclinical studies
The volume of distribution and plasma clearance of protein pharmaceuticals over a wide molecular weight range (6000 to 98 000 Daltons) seem to follow well defined, size related physiological relations, and preclinical pharmacokinetic studies provide reasonable estimates of human disposition after interspecies scaling. The plasma clearance data for PEG sTNF-RI can be scaled from rats and baboons to predict the pharmacokinetics in humans (fig 11   73 ). However, as chimpanzees (Pan troglodytes) are the closest relative to humans and are of a similar body weight (50 kg) the pharmacokinetics in chimpanzees would be expected to be similar to those in humans. For a 70 kg human, one would predict the initial volume of distribution of 60-70 ml/kg, a steady state distribution volume of 
Summary
Based on the results from our preliminary pharmacology, pharmacokinetic, and toxicology studies, as well as other recently published studies demonstrating clinical proof of concept with anti-TNF compounds, 63 65 the initial clinical target of PEG sTNF-RI will be RA. A phase 1 study with PEG sTNF-RI has been conducted that is designed as a dose escalating pharmacokinetic trial in RA patients. This trial uses both weekly and bimonthly subcutaneous dosing regimens to assess the safety, immunogenicity, and potential eYcacy in RA patients. 74 Time (days) after first dose PEG sTNF-RI in plasma (ng/ml) 35 Mean (SD) Target plasma concentration in humans Figure 11 Allometric scaling of clearance. Clearance of PEG sTNF-RI in humans projected to be 117 ml/h I80 Edwards group.bmj.com on July 7, 2017 -Published by http://ard.bmj.com/ Downloaded from
